The brief
- Qalsody: FDA accelerated approval April 2023, EU approval May 2024, for ALS caused by SOD1 mutations.
- ATLAS phase 3 tests whether starting tofersen before symptoms can delay or prevent ALS.
Programs
Biogen, one program
Updated 1 May 2024
Research · Proto · Pilot · Deploy · Scaling
Peers
Company & funding
- HQ
- US
Partners & customers
- PartnerIonis Pharmaceuticals
Ionis discovered tofersen; Biogen licensed, developed and sells it.